Stock IVBIY INNOVENT BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Innovent Biologics, Inc. OTC Markets

Equities

IVBIY

US45783L1017

Delayed OTC Markets
Other stock markets
 15:01:58 01/04/2024 BST 		5-day change 1st Jan Change
19.48 USD +4.39% Intraday chart for Innovent Biologics, Inc. -.--% -6.75%
05-07 Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer CI
04-30 Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Head-to-head Superiority to High-dose Dulaglutide, Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints
AQ
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer
CI
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer
AQ
Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024
CI
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer
CI
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer
AQ
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer
CI
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
AQ
Hutchmed endometrial cancer treatment application accepted for review
AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination
MT
HSBC in special payout on Canada sale; Astra FDA win
AN
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority
MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
CI
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application
CI
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows
MT
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
CI
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
AQ
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%
MT
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1801 Stock
  4. IVBIY Stock
  5. News Innovent Biologics, Inc.